ASX:ENPPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals
Entropy Neurodynamics Ltd
$0.035
$0.001 (1.41%)
Day Range
$0.035 – $0.036
52 Week Range
$0.025 – $0.046
Volume
531.49K
Avg Volume (10D)
1.54M
Market Cap
$57.11M
Price Chart
Market Statistics
Open$0.036
Previous Close$0.036
Day High$0.036
Day Low$0.035
52 Week High$0.046
52 Week Low$0.025
Valuation
Market Cap57.11M
Shares Outstanding1.63B
Price to Book7.29
Trading Activity
Volume531.49K
Value Traded18.74K
Bid$0.034 × 2,402,892
Ask$0.035 × 32,173
Performance
1 Day2.86%
5 Day2.86%
13 Week28.57%
52 Week12.50%
YTD9.09%
Technical Indicators
RSI (14)56.54
50-Day SMA$0.034
200-Day SMA$0.034
Latest News

Biotechnology
Entropy Neurodynamics Reports Breakthrough Results from Phase 2a TRP-8802 Study for Treating IBS
Entropy Neurodynamics announces Phase 2a TRP-8802 IBS results: 75% responders, clear gut-brain axis effect; de-risks program ahead of TRP-8803 trials.

Biotechnology
Entropy Neurodynamics' TRP-8803 Trial Shows Repeatable Psychedelic Effects in BED Study
Entropy Neurodynamics reports repeatable psychedelic effects in TRP-8803 BED trial; Cohort 2 enrollment advancing; R&D incentives boost cash runway.

Biotechnology
Entropy Neurodynamics Granted Australian Patent for TRP8803 to Treat Chronic Pain and Psychiatric Conditions
Entropy Neurodynamics (ASX: ENP) granted Australian patent for TRP8803 (IV psilocybin) for chronic pain and neuropsychiatric disorders; protection to 2042.